▟ Vinebot intrinsic value, daily

← back

COO Cooper Companies (The)

healthcare · valued with opus medium conviction · deep-dived 2026-10-15

SELL
Intrinsic value$26.06
Price (at call)$54.88
Margin of safety -52.5%
vs market (rating basis) -21.5%

Oligopoly contact lens franchise priced for stagnation; margin normalization alone covers today's price.

The story

Cooper is a two-segment medtech: CooperVision is the #3 global soft contact lens maker in a rational four-player oligopoly with recurring, consumer-driven demand (daily silicone hydrogels, myopia control via MiSight), and CooperSurgical is a fertility and women's health business built through acquisitions. It is a mature, mid-single-digit grower. GAAP margins are held down by heavy acquisition amortization and restructuring, and its acquired goodwill makes the reported capital base look bloated. The stock has de-rated on slowing lens growth, a weak fertility segment and activist pressure, so the question is whether margins can be normalized, not whether the franchise survives.

Growth of about 5% tracks the contact lens market plus share gains in dailies and myopia control, below the 7.3% historical CAGR, which was helped by acquisitions. I set the target margin at 21%, between GAAP (13-18%) and adjusted (~25%), because amortization and recurring restructuring are partly real costs; cost programs and portfolio pruning support a 5-year glide path. Sales-to-capital of 1.2 is a marginal organic figure: the reported 0.39 is distorted by acquisition goodwill and would wrongly penalize organic growth. That lens is why the baseline value of $0.83 is not credible.

Value drivers

Revenue growth (Y1)5.0%
Terminal growth3.0%
Forecast horizon8y
Target operating margin21.0%
Years to target margin5
Sales-to-capital1.20
Beta0.90
Failure probability2.0%
Cost of capital (WACC)8.5%
Terminal WACC8.9%

Valuation bridge

PV of explicit FCFF2.62B
PV of terminal value4.83B
Equity value4.96B
÷ shares → per share$26.06

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 4.45B 5.0% 14.6% 430.29M 176.54M 253.75M 233.76M
2 4.66B 4.7% 16.2% 499.78M 174.77M 325.01M 275.83M
3 4.86B 4.4% 17.8% 573.30M 171.92M 401.38M 313.83M
4 5.07B 4.1% 19.4% 650.57M 167.95M 482.62M 347.63M
5 5.26B 3.9% 21.0% 731.25M 162.85M 568.40M 377.17M
6 5.45B 3.6% 21.0% 757.36M 156.60M 600.76M 367.25M
7 5.63B 3.3% 21.0% 782.25M 149.22M 633.03M 356.50M
8 5.80B 3.0% 21.0% 805.71M 140.72M 665.00M 345.01M

Key risks

  • Contact lens share loss or price pressure from J&J, Alcon and Bausch in dailies and toric lenses
  • Fertility and IVF demand stays cyclical and soft, and CooperSurgical gets sold at a discount
  • Leverage (about $2.4B net debt) plus serial M&A destroying value instead of improving margins

Catalysts

  • Activist-driven portfolio action (separating or selling CooperSurgical) or a margin-focused restructuring
  • MiSight myopia control adoption and new daily silicone hydrogel launches lifting organic lens growth back above 6%

History

DatePriceIntrinsicMoSRating
2026-10-15$54.88 $26.06 -52.5% SELL
2026-08-26$73.04 $0.00 -100.0% STRONG SELL
2026-07-06$74.20 $6.12 -91.7% STRONG SELL
2026-06-23$66.15 $4.70 -92.9% STRONG SELL